EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epigenetic Inactivation of RIPK3-Dependent Necroptosis Augments Cisplatin Chemoresistance in Human Osteosarcoma

Aditya Sharma, Daniel Pettee, Christine Mella iD, Catherine Hord, Maximilian Brockwell, Samantha Hardy, Hope C Ball, Fayez F Safadi, Steven J Kuerbitz

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26083863 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Aditya Sharma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology Oncology, Akron Children's Hospital, One Perkins Square, Akron, OH 44308, USA. Hauptthemen laut MEDLINE: Cisplatin, Receptor-Interacting Protein Serine-Threonine Kinases, Osteosarcoma, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma (OS) is the most common primary bone malignancy in children and adolescents. Unfortunately, drug resistance limits the efficacy of chemotherapeutic treatment and compromises therapeutic outcomes in a substantial proportion of cases. Aberrant CpG island methylation-associated transcriptional silencing contributes to chemoresistance in pediatric solid tumors. Here, using whole-genome DNA methylation screening on 16 human primary OS specimens, we identify receptor interacting protein kinase-3 (RIPK3), a molecular regulator of the necroptosis programmed cell death pathway, as a gene target of aberrant CpG methylation and demonstrate its role in human OS chemoresistance. We validated these findings via enforced expression and DsiRNA silencing, and evaluated the role of RIPK3 in cisplatin chemosensitivity and necroptosis activation through MLKL phosphorylation. We found that CpG island methylation results in RIPK3 silencing in primary human OS samples and cell lines. Enforced RIPK3 expression significantly enhanced cisplatin cytotoxicity in OS cells and DsiRNA knockdown reversed the cisplatin-sensitive phenotype. In cells with enforced RIPK3 expression, cisplatin treatment significantly increased phosphorylation of both RIPK3 and its target, MLKL, indicative of induction of necroptosis. Here, we identify RIPK3 as an important mediator of chemoresistance in OS and a potential pharmacologic target to improve chemotherapy efficacy in drug-resistant tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinReceptor-Interacting Protein Serine-Threonine KinasesOsteosarcomaDrug Resistance, NeoplasmNecroptosisEpigenesis, GeneticBone NeoplasmsHumansCell Line, TumorDNA MethylationCpG IslandsGene Expression Regulation, NeoplasticAntineoplastic AgentsProtein KinasesAdolescentPhosphorylationFemale

Stichwörter der Autor:innen

CpG islandsRIPK3chemoresistancenecroptosisosteosarcoma

Substanzen

CisplatinReceptor-Interacting Protein Serine-Threonine KinasesRIPK3 protein, humanAntineoplastic AgentsMLKL protein, humanProtein Kinases

Autor:innen und Institutionen

  • Division of Hematology Oncology, Akron Children's Hospital, One Perkins Square, Akron, OH 44308, USA.
  • College of Medicine, Northeast Ohio Medical University, 4029 State Route 44, Rootstown, OH 44272, USA.
  • Rebecca D. Considine Research Institute, Akron Children's Hospital, One Perkins Square, Akron, OH 44308, USA.
  • University Hospitals Health Systems, 11100 Euclid Ave, Cleveland, OH 44106, USA.

ORCID-Profile: Christine Mella

Zitieren

APA

Sharma, A., Pettee, D., Mella, C., Hord, C., Brockwell, M., Hardy, S., Ball, H. C., Safadi, F. F., & Kuerbitz, S. J. (2025). Epigenetic Inactivation of RIPK3-Dependent Necroptosis Augments Cisplatin Chemoresistance in Human Osteosarcoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26083863

Vancouver

Sharma A, Pettee D, Mella C, Hord C, Brockwell M, Hardy S, et al. Epigenetic Inactivation of RIPK3-Dependent Necroptosis Augments Cisplatin Chemoresistance in Human Osteosarcoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26083863

BibTeX
@article{Sharma2025,
  author = {Sharma, Aditya and Pettee, Daniel and Mella, Christine and Hord, Catherine and Brockwell, Maximilian and Hardy, Samantha and Ball, Hope C and Safadi, Fayez F and Kuerbitz, Steven J},
  title = {Epigenetic Inactivation of RIPK3-Dependent Necroptosis Augments Cisplatin Chemoresistance in Human Osteosarcoma},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26083863}
}
Kostenlos starten →